Reliance Medical Completes Nearly RMB 100 Million Series A2+ Financing to Advance Clinical Mass Spectrometry Solutions

VCBeat (WeChat: vcbeat) has learned thatReliable Med (Hangzhou) Medical Technology Co., Ltd. (hereinafter referred to as “Reliable Med” or the “Company”) recently completed an A2+ round of financing amounting to nearly RMB 100 million; this round was led by Industrial Securities Innovation Capital, with Suxin Venture Capital participating as a co-investor.This round of financing will be used to accelerate the clinical translation, upgrading, capacity expansion, and regulatory filing of the company’s mass spectrometry hardware and reagent products; to strengthen channel development and clinical market promotion; and to further advance the application of mass spectrometry technology in clinical laboratories, establishing it as a standardized, automated, intelligent, and user-friendly testing platform for clinical laboratories.

Reliable Med (Hangzhou) Medical Technology Co., Ltd., established in 2019, is a national high-tech enterprise specializing in the research and development, manufacturing, sales, and services of in vitro diagnostic products. Since its inception, the company has been dedicated to research in the field of clinical mass spectrometry analysis. After years of diligent efforts, it successfully completed the registration of China’s first clinically graded inductively coupled plasma mass spectrometer with fully independent intellectual property rights in April 2021, launched it onto the market, and gained widespread recognition from domestic medical institutions. Embracing innovation and closely aligning with clinical needs, the company is expanding from a single product line to multiple product lines, penetrating the global market from its domestic base, and evolving from product automation to intelligence. Currently, over 60% of its employees hold master’s or doctoral degrees. The company holds more than one hundred core patents covering software, hardware, and applications, leads and participates in the development of five industry standards, and has obtained ISO 13485 Quality Management System and GB/T 29490-2013 Intellectual Property Management System certifications, establishing itself as an innovative leader in the medical mass spectrometry industry. It has established two major R&D centers in Hangzhou and Suzhou, featuring a GMP-compliant R&D and production base exceeding 11,000 square meters. Consistently adhering to its mission, Reliable Med remains customer-centric and market-oriented, continuously creating value for human health through sustained product and technological innovation.

 Inorganic Mass Spectrometry Detection System V1.0

Fully Automated Inorganic Mass Spectrometry Detection System (High-Throughput) Version 2.0

Image source: Reliable Med

Regarding the success of this round of financing,Company Founding Teamstated: “We extend our gratitude to our investors for their trust, and to friends from all sectors of society who have consistently paid attention to and supported Reliable Med. The company will take this as impetus to continue dedicating itself wholeheartedly to the R&D and industrialization of its clinical mass spectrometry product pipeline, providing high-quality products and services to clinical end-users, and making laboratory testing more precise, reliable, and efficient.”

Xiang Jun, Vice President of Xingzheng Innovation Capital“Xingzheng Capital has continuously researched and tracked the upstream life sciences industry for many years, firmly believing in the development potential of mass spectrometry technology in China and the vast market space behind it. As a leading enterprise in China’s mass spectrometry sector, Reliable Med has been constantly overcoming critical bottlenecks in clinical mass spectrometry, promoting the sustainable development of precision medicine in China. We look forward to the company continuing to make solid progress, launching new solutions, breaking the monopoly of imported equipment in high-end mass spectrometry applications, and making greater contributions to advancing clinical mass spectrometry in China.”

Suxin Venture Capital Team“It is stated that mass spectrometry represents a critical niche within clinical laboratory testing, a sector long dominated by imported foreign instruments. Reliable Med is an enterprise in which we have firm, long-term confidence. Focusing on research and innovation in clinical mass spectrometry, Reliable Med has rapidly grown into a high-tech enterprise centered on ‘mass spectrometry/chromatography/fully automated biological sample hardware plus supporting diagnostic reagent development.’ This expansion has broadened the application of domestically produced mass spectrometry technologies in clinical diagnostics, significantly improving and meeting clinical needs. With the ongoing development of Reliable Med’s new generation of high-quality products, we believe the pace of domestic substitution in this field will further accelerate. Reliable Med has also established a R&D base in Suzhou. Su Xin Venture Capital will continue to support the company’s development as always. We are honored to participate in this round of investment and look forward to Reliable Med’s continuous innovation and breakthroughs!”

Xingzheng Innovation Capital Management Co., Ltd. was established in 2010 as a wholly-owned private equity fund subsidiary of Industrial Securities Co., Ltd. (SH601377), with the total scale of funds under management and services exceeding RMB 10 billion. Leveraging its equity investment expertise and the platform advantages of being a securities firm subsidiary, Xingzheng Capital is committed to providing multi-faceted post-investment value-added services to its portfolio companies, fostering their healthy growth and sustainable development, and helping them excel from good to great.

Suzhou Suxin Yihe Investment Management Co., Ltd. was established in 2012. Serving high-quality enterprises based in Suzhou and the Yangtze River Delta region, the company focuses on the healthcare and wellness sector. It is committed to investing in premium medical and health enterprises driven by innovative technologies, particularly those with cutting-edge expertise and industry-leading R&D and innovation capabilities, aiming to help cultivate a cohort of high-quality medical enterprises with international competitiveness.